Skip to main content

lapatinib

Generic: lapatinib·Brand: Tykerb

lapatinib: 2 clinical trials tracked.

lapatinib evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about lapatinib, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence2 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1

NCT03523585Registry updated 2026-02-27·Phase 3
Completed

Primary endpoint: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine

InterventionalRandomizedopen608 enrolledStarted 2018-08Completion 2025-1250 sites · Australia, United StatesDaiichi Sankyo

Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer

NCT01273610Registry updated 2026-06-25·Phase 2
Active, not recruiting

Primary endpoint: Percent of Participants With Grade 3 or Higher Non-hematological Toxicities and Symptomatic Congestive Heart Failure

Interventionalopen40 targetStarted 2011-04Completion 2027-048 sites · United StatesCity of Hope Medical Center